Overall, these results suggest that anti-oxidant agents preferentially suppress the growth of HER2-overexpressing cancer cells, whereas promoting an antioxidant status in HER2-positive breast cancer cells is not sufficient to down-regulate HER2 expression in human breast cancer cells. The gene discussed is ERBB2; the disease is breast carcinoma.